Trial Profile
A Prospective Observational Cohort Study to Monitor and Compare the Occurrence of Hypersensitivity Reaction and Hepatotoxicity in Patients Receiving Dolutegravir (With and Without Abacavir) or Other Integrase Inhibitors (With or Without Abacavir)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary) ; Abacavir; Elvitegravir; Raltegravir
- Indications HIV-1 infections
- Focus Adverse reactions
- Acronyms PASS
- Sponsors ViiV Healthcare
- 05 Feb 2020 Status changed from active, no longer recruiting to completed.
- 02 Nov 2017 New trial record